Laboratorios Farmacéuticos ROVI announces the full-year results for 2024, a key year for setting the bases for ROVI’s future, focused on increasing our production capacities in the contract manufacturing business and reinforcing the company’s internationalisation with Risperidone ISM®.
In 2024, the company obtained operating revenue of 763.7 million euros; EBITDA of 207.4 million euros; and a net profit of 136.9 million euros.
The contract manufacturing business (CDMO) decreased 18% compared to 2023, dropping to 336.2 million, as a consequence of:
– lower revenue related to the manufacture of the COVID-19 vaccine compared with 2023, when ROVI booked higher revenue related to the production of the “pandemic” COVID-19 vaccine; and – lower revenue related to the activities carried out to prepare the plant for vaccine production under the agreement with Moderna.
Positive evolution of Okedi® (Risperidone ISM®), which had total sales of 28.8 million euros in 2024. Okedi® sales in 2024 doubled those of 2023.
Sales of the heparin franchise (low-molecular-weight heparins (LMWH) and other heparins) slightly decreased by 1% to 248.7 million euros in 2024, mainly due to lower orders from enoxaparin partners throughout the year.
In December 2024, for the fifth year running, ROVI improved its ESG risk rating awarded by Sustainalytics, achieving a low risk of 16.1, compared to 16.4 the previous year. The Company was placed fifth in the world ESG risk ranking from among the 424 companies evaluated in the pharmaceutical industry.